Slide 1. Slide 2. Slide 3. Screening and Surveillance for the Early Detection of Gastric Cancer. Case FG. Endoscopy

Size: px
Start display at page:

Download "Slide 1. Slide 2. Slide 3. Screening and Surveillance for the Early Detection of Gastric Cancer. Case FG. Endoscopy"

Transcription

1 Slide 1 Screening and Surveillance for the Early Detection of Gastric Cancer Society of Gastroenterology Nurses and Associates April 11, 2015 Salina Lee, MD Assistant Professor of Medicine Division of Digestive Diseases Rush University Medical Center Slide 2 63 year old African American male admitted for fatigue PMHx: HTN, GERD Meds: antihtn, PPI FHx: noncontributory SocHx: grew up in Chicago, social EtOH, never tobacco ROS: (+) weight loss - ~20lbs/3-4 months Case FG Exam unremarkable Labs: Hb 7.4, microcytic Slide 3 Endoscopy

2 Slide 4 How could this happen Slide 5 Screening and surveillance for the early detection of GASTRIC CANCER Slide 6 Background Gastric cancer 4 th most common cancer in the world 937,00 new cases per year, accounting for nearly 10% of all new cancers 2 nd highest cause of cancer-related deaths worldwide 700,000 deaths per year Wide global variation 2/3 cases in developing countries Busuttil RA and Boussioutas A. J Gastoenterol and Hepatology 2000;24: de Vries AC et al. Helicobacter2007;12:1-15 devries AC and Kuipers EJ. Helicobacter 2007;12:22-31

3 Slide 7 Mechanism Mechanism of gastric carcinogenesis complicated and largely unknown Majority is associated with histologically recognizable premalignant stages first described by Pelayo Correa in mid 1970 s Chronic H. pylori infection is thought to initiate a premalignant cascade Sequence involves chronic superficial gastritis, atrophic gastritis, intestinal metaplasia, dysplasia, and invasive neoplasia Busuttil RA and Boussioutas A. J Gastoenterol and Hepatology 2000;24: Slide 8 Burden of Disease High incidence East Asia In the west, though incidence is Central America low, mortality remains high because South America index of suspicion is low Netherlands Late diagnosis 5 yr survival <20% 8.6 Early detection 5 yr survival as high as 90% China China US 5.7 Japan Japan Sudan 2.5 Of note, it is not clearly associated with the developing Globocan 2008: cancer incidence, mortality and prevalence worldwide. IARC Cancer Base No. 5 version 2.0, IARC Press 2008 world eg: Africa Busuttil RA and Boussioutas A. J Gastoenterol and Hepatology 2000;24: de Vries AC et al. Helicobacter2007;12:1-15 Slide 9 UNANSWERED ASGE Guidelines QUESTIONS Benefits of surveillance has been evaluated and known How H. pylori and should who be should treated be if tested found for H. pylori? What If low grade could dysplasia be done is before detected, dysplasia? surveillance EGD with topographic at the point mapping of intestinal metaplasia Who For US, is the considered progression higher of IM than to cancer average is low and risk? surveillance is not indicated for the average risk patient ASGE guideline: the role of endoscopy in the surveillance of premalignant conditions of the upper GI tract. GIE 2006;63:

4 Slide 10 RISK FACTORS FOR GASTRIC CANCER Slide 11 Risk Factors Habitat H. pylori Host Smoking Nitrate high diet Low fresh fruit and vegetables Alcohol use low socioeconomic class blood group A familial occurrence of gastric cancer H. pylori virulence Host genetics Interaction Slide 12 H. pylori discovered 1980s NIH consensus conference recognized HP as a cause of gastric and duodenal ulcers 1994 International Agency for Research on Cancer (IARC) and World Health Organization (WHO) classified H. pylori as a Class I (definite) 1994 human carcinogen We don t Cigarette smoking screen HPV H. Pylori HCV The most successful human pathogen ~50% human population infected Screen for class 1 carcinogens Busuttil RA and Boussioutas A. J Gastoenterol and Hepatology 2000;24: devries AC and Kuipers EJ. Helicobacter 2007;12:22-31 Malfertheiner P et al. Gut 1012; 61:

5 Slide 13 Complicated interrelationship genetic bacterial environs non-neoplastic malignancy Majority of the course is benign Slide 14 Issue of geography East vs. West Japan Western Europe HP 60% HP 40% (+) (-) (+) (-) AG: 80% AG: 10% AG: to 60% AG: 5-10% IM: 40-50% IM: 40% IM: 5% IM: 5-10% The pattern to notice: When HP (+) higher incidence of AG or IM regardless of world region de Vries AC et al. Helicobacter2007;12:1-15 Slide : 12 case control studies within prospective cohorts H. Pylori positivity increases risk of developing gastric cancer 6 fold 2008: Prospective study over 9.4 years Patients infected with h. pylori have 10.9 fold higher chance of gastric cancer than uninfected 2007: Meta-analysis f/u long term impact of HP eradication on gastric ca risk 8 studies, months f/u IM may be a point of no return where progression to gastric cancer is inevitable Suggests HP eradication should precede onset of metaplastic lesions Argument for screening for H.Pylori Gut 2001;49: Kim N et al. J Clin Gastroenterol 2008;42: Rokkas T et al. Helicobacter 2007;12:32-38

6 Slide 16 H. Pylori screening Gastric MALT lymphoma Active peptic ulcer disease Past history of documented peptic ulcer Test and treat for dyspepsia (<55yo and no alarm symptoms) Kalaghchi B et al. J Clin Gastroenterol 2004;38: Slide 17 H. Pylori screening Patients who are on ppi longterm Prior to treatment with NSAIDs Unexplained iron deficiency anemia Unexplained vitamin b12 deficiency *Assymptomatic not tested Slide 18 New recommendations Population based screening for high risk groups Asian pacific guidelines European guidelines ACG guidelines Population based screening for high risk groups Describe high risk populations but consider strategies for screening such groups as controversial WHO to screen Talley NJ et al. Gastric cancer consensus conference recomends Helicobacter pylori screening and treatment in asymptomatic persons from high-risk populations to prevent gastric cancer. AJG 2008;103:510 Malfertheiner P et al. Management of Helicobacter pylori infection the Maastricht IV/Florence Consensus Report. Gt 2012;61:646 Chey WD et al. Practice Parameters Committee of the ACG. ACG guideline on the management of Heliocbacter pylori infection. AJG 2007;102:1808

7 Slide 19 Case FG Urea breath test: negative Endoscopy: No H. pylori?... Pathology: Mass: invasive adenocarcinoma Random: atrophic gastritis and multiple foci of intestinal metaplasia involving the antrum and corpus of the stomach H. pylori negative Slide 20 Choosing the right test HOW to screen Pretest Clinical setting probability Sensitivity and specificity Cost effectiveness and availability Gatta l. Am J Gastro 2004;99:823 Slide 21 Endoscopic testing Rapid Urease Test Histology Culture Hydrolysis of urea Sens 90-95% Spec % Sens >95% Spec >95% Limited by cost, not usually needed Only for sensitivity in refractory disease Chey W et al. Am J Gastroenterol 2007;102:

8 Slide 22 Non-invasive testing Breath urea Stool Ag Serology Hydrolysis of urea Sens 88-95% Spec % False negatives Detects HP via enzyme immunoassay Sens 94% Spec 86-92% Recommended as test of choice Most accurate noninvasive test for active HPI Gatta l. Am J Gastro 2004;99:823 Malfertheiner P et al. Gut 1012; 61: Slide 23 Watch out for false negatives Meds Blood Mucosa Decreased sensitivity Gatta l. Am J Gastro 2004;99:823 Slide 24 Mechanism of decreasing sensitivity - increase in gastric ph - rise in periplasmic ph in HP - decreases internal urease activity - decrease bacterial density - may be responsible for decreased sensitivity in both tests Gatta l. Am J Gastro 2004;99:823

9 Slide 25 Aim: to determine if sensitivity of Urea Breath Test (UBT) and H. pylori Stool Antigen Test (HpSA) is decreased with PPI Prospective single blind randomized study n=152 patients/6 mo with h. pylori infection HP infection rapid urease (+) and histology or culture (+) alone Gatta l. Am J Gastro 2004;99:823 Slide 26 n=152 eligible n=72 enrolled n=24 omeprazole 20/d n=24 esomeprazole 40mg/d n=24 AlOH 800mg/d UBT HpSA UBT HpSA UBT HpSA 2 weeks treatment 2 weeks treatment 2 weeks treatment UBT Stool Test UBT Stool Test UBT Stool Test Gatta l. Am J Gastro 2004;99:823 Slide 27 Results Sensitivity: UBT Stool Test PPI Antacid PPI Antacid Baseline After treatment % 100% 100% 97.8% 90.0% 100% 83.0% 90.0% Conclusion: PPI decreases sensitivity of UBT and HpSA Antacid will not alter sensitivity of UBT or HpSA Gatta l. Am J Gastro 2004;99:823

10 Slide 28 And Ranitidine or Bismuth? False negative rates PPI UBT 14-52% HpSA 15-36% Bis 44-55% 15-25% H2B 5-18% 5% Gatta l. Am J Gastro 2004;99:823 Laine L et al / Manes G et al / Bravo L et al Parente F et al / Connor S et al 1999 / Dulbecco P et al / Savarino V et al Savarino V et al. Am J Gastroenterol 2001;96: Bravo L et al. Am K Gastroenterol 1999; 94: Slide 29 Points to consider when using tests of active infection How soon? As early as one day When returns to positivity? Reliably after 2 weeks off PPI Ranitidine may have tolerance effect Who s on a PPI? 4.0% (2002) 9.2% (2009) 23.4% 37.8% 79.7% Gatta l. Am J Gastro 2004;99:823/ Patterson B et al. J Am Med Dir Assoc 2013; 13: Ajumobi A et al. J Manag Care Pharm 2012;18:63-7 / De Souto Barreto P et al. J Am Med Dir Assoc 2013;14:265-9 Rotman S et al. PLoS One 2013;8:e56060 / Reimer C et al. Aliment Pharmacol Ther 2009;30: Mana F et al. Dig Liver Dis 2005;37:28-32 Slide 30 Case FG Urea breath test: negative Endoscopy: Patient No H. pylori?... FG was on PPI! Pathology: Mass: invasive adenocarcinoma Random: atrophic gastritis and multiple foci of intestinal metaplasia involving the antrum and corpus of the stomach H. pylori negative

11 Slide 31 Watch out for false negatives Meds Blood Mucosa Decreased sensitivity Gatta l. Am J Gastro 2004;99:823 Slide 32 Acute GI bleeding Meta-analysis of 23 studies Mean prevalence 63-80% Multiple diagnostic modalities assessed Gold standard for diagnosis based on at least one independent diagnostic method 0.67 RUT Severe limitation: significant heterogeneity 0.70 Histo 0.93 UBT 0.87 HpSA high prevalence setting raise index of suspicion Gisbert JP et al. Am J Gastroenterol 2006; 101: Slide 33 Watch out for false negatives Meds Blood Mucosa Decreased sensitivity Gatta l. Am J Gastro 2004;99:823

12 Slide 34 Gastritis and chronic inflammation were severe when H. pylori existed in the gastric mucosa, as expected In contrast, the degree of atrophic gastritis and IM was more severe in seropositive only group compared to other two groups (seropositivity + histology positive, and seronegative) Suggest that the progression of atrophic gastritis and intestinal metaplasia seems to drive H. pylori out of the gastric mucosa H. pylori IgG positivity with negative invasive tests represents past infection rather than false negative Kang HY et al. Dig Dis Sci 2006; 51: Gisbert JP et al. Am J Gastroenterol 2006; 101: Slide 35 Case FG Urea breath test: negative Endoscopy: Did this confound No H. pylori?... results in patient FG? Pathology: Mass: invasive adenocarcinoma Random: atrophic gastritis and multiple foci of intestinal metaplasia involving the antrum and corpus of the stomach H. pylori negative Slide 36 Non-invasive testing Breath urea Stool Ag Serology Hydrolysis of urea Detects HP via enzyme Sens 88-95%/spec Useful: 95- immunoassay 100% High pretest probability Sens 94%/spec (ulcer), 86-92% False positives rare False in UGIB - May treat based on positive serology False negatives cross-reactivity with Confirm negative serology acid suppressant blood therapy (40%) False negative bismuth Useful: (55%) ppi and bismuth (not antibiotics Low pretest probability h2b) (young dyspepsia, low prevalence area) Negative useful to exclude infection Confirm positive serology Elisa to detect IgG Sens % Spec 76-96% Prevalence affects ppv If <20% (+) HP active infection ~50% of the time Gatta l. Am J Gastro 2004;99:823 Malfertheiner P et al. Gut 2007;56:772 Chey WD et al. Am J Gastroenterol 2007;102:1808

13 Slide 37 Urea breath test: Negative Case FG Endoscopy: H. Pylori Serology No POSITIVE H. pylori?... Pathology: Mass: invasive adenocarcinoma Random: atrophic gastritis and multiple foci of intestinal metaplasia involving the antrum and corpus of the stomach H. pylori negative Slide 38 The downsides? Not active infection Not cost effective Abx complications Abx resistance 6-12 months to clear Ab Ask the patient! Economic model: 50 yo Japanese Americans, screening with HP serology was more cost effective than mammography C. diff, rare, case report Not usually w. standard HP Rx Most significant issues with 3 rd gen cephalosporins, FQ, Abx for S. aureus, carbapenems Deshpande et al. Practice Based Pharmacology 2013 WHO fact sheet 2014; No 194 Parsonnet et al. Lancet 1996;348:150 Slide 39 H. pylori antibody is FOREVER Titers decline by approximately 50% at 3 months 60% have undetectable titers at 18 months After therapy, seroconversion from detectable to undetectable levels have specificity of 100% for detecting the eradication Biopsy proven infection 18 moundetectable IgG Detectable IgG 65% 35% Bx proven cure Persistent gastritis Useful >1 yr post tx eradication Feldman M et al. JAMA 1998; 280:363 Lerang F et al. Scan J Gastroenterol 1998; 33:710-5

14 Slide 40 The prevalence of disease is low The question: what is the prevalence among patients in Chicago african american caucasian 33% 32% american indian hispanic asian 0.5% 29% 5.5% Eastern Europe? Poles and Serbians in Chicago are their largest ethnic communities outside of Poland and Serbia en.wikipedia.org/wiki/file:african_american_population_by_census_tract_in_chicago,_il_(2011).svg Slide 41 Slide 42 based on serology 34% 26% 26% Cauasian Prevalence of H. pylori asymptomatic patients adjusted for age, income, education, other clinical factors African American 70% 66% 53% Sero-positivity significantly higher in African American and Hispanic population Hispanic N=485, Houston 65% N=108, Houston 62% n=7465, Nhanes Graham D et al. Gastroenterology 1991;100: Malaty H et al. Gastroenterology 1992;103:813-6 Everhart J et al. J Infect Dis 2000;181:

15 Slide 43 based on histology 24% 15% Cauasian Prevalence of H. pylori African American 28% 29% Clinical symptoms were not associated with HP positivity (but ethnicity was) 40% 36% Hispanic N=248 egds symptomatic n=253 assymptomatic Smith J et al Conn Med 2009;713:133-7 Portocarrero D et al. J Clin Gastroenterol 2012;46:431-2 Slide 44 34% 26% 26% 21% The prevalence is decreasing 2012 update Overall seroprevalence decreased from 33% to 31% Cauasian African American 70% 66% 53% 52% decline in HP seroprevalence affects primarily the Caucasian population Hispanic N=485, Houston 65% N=108, Houston 62% n=7465, Nhanes 64% 2012 update Graham D et al. Gastroenterology 1991;100: Malaty H et al. Gastroenterology 1992;103:813-6 Everhart J et al. J Infect Dis 2000;181: Slide 45 Overall Caucasian African American Hispanic Everhart J et al. J Infect Dis 2000;181: Grad Y et al. Am J Epidemiol 2012;175:54-9

16 Slide 46 Does treatment reduce risk of gastric cancer? High incidence areas (China, Japan, Columbia) Meta-analysis trials significantly lower rate of gastric cancer in patients randomized to eradication 1.1 vs. 1.7% (RR 0.65,95% CI ) China, 15 year follow up Placebo controlled trial, n=3365; 14.7 yr f/u significant reduction in gastric cancer incidence in patients who underwent eradication 3.0% vs. 4.6 %(OR 0.61,95% CI ) Taiwan, 5 year follow up Eradication seem to reduce the risk of gastric cancer in high risk patients Mass eradication study over 5 years There was decrease in pud and gastric cancer Fuccio L et al. Ann Intern Med 2009;151:121 Ma JL et al. J Natl Cancer Inst 2012;104:488 Lee YC et al. Gut 2013;62:676 Slide 47 UNANSWERED ASGE Guidelines QUESTIONS Benefits of surveillance has been evaluated and known How H. pylori and should who be should treated be if found tested for H. pylori? What If low grade could dysplasia be done is detected, before dysplasia? surveillance EGD with topographic at the point mapping of intestinal metaplasia Who For US, is the considered progression higher of IM to than cancer average is low and risk? surveillance is not indicated for the average risk patient ASGE guideline: the role of endoscopy in the surveillance of premalignant conditions of the upper GI tract. GIE 2006;63: Slide 48 Gastric Intestinal Metaplasia? Adaptive response to environmental stimuli such as HP infection, smoking, high salt intake Gastric mucosa is replaced by mucosa that resembles intestinal epithelium Morphologically characterized by mucus secreting goblet cells Typically assymptomatic My be associated with achlorhydria sibo and bloating, flatulence, abdominal discomfort, and diarrhea High association of IM with gastric cancer Leung WK et al. Aliment Pharmacol Ther 2002;16: Filipe MI et al. Int J Cancer 1994;57: Busuttil RA and Boussioutas A. J Gastoenterol and Hepatology 2000;24:

17 Slide 49 Japan: IM conferred a 6.4x higher risk of developing gastric cancer Slovenia: Patients with IM have a >10 fold increased risk of developing gastric cancer Increased risk of gastric cancer are from varying populations (not just Asia) China: OR for gastric cancer ranged from 17.1 to 29.3 Filipe MI et al. Int J Cancer 1994;57: Uemura N et al. N Engl J Med 2001;345:784-9 You WC et al. Int J Cancer 1999;83: Slide 50 RATIONALE FOR/AGAINST SURVEILLANCE? Slide 51 Against surveillance Developed countries: low prevalence, low yield, high cost Gastric IM is difficult to recognize endoscopically (unlike premalignant lesions of esophagus and colon) Findings at conventional endoscopy often still correlate poorly with histology diagnoses Differences in training and approach from Western vs. Asian countries (especially Japan), where lesions are frequently established on endscopy vs. histologic evaluation of random biopsies

18 Slide 52 Endoscopic findings may be subtle Slide 53 Which is intestinal metaplasia? Slide 54

19 Slide 55 Pro screening/ surveillance Many compelling reasons Leung WK et al. Aliment Pharmacol Ther 2002;16: Slide 56 Compelling reason # 1 ERADICATION WORKS Aim: investigate whether the eradication of HP reduces risk of developing gastric cancer Nippon Fukuyama Hospital outpatient clinic, n=1342 consecutive patients with PUD and who had received HP eradication Index endoscopy n=1342 evaluate ulcers, background gastric mucosa, HP infection Gastric atrophy classified by histology. IM diagnosed endoscopically as absent/present HP infection = positive bacterial culture from endoscopic biopsy and urease test Take S. et al. Am J Gastroenterol 2005;100: Slide 57 Methods evaluate ulcers, background gastric mucosa, HP infection 776 gu Index endoscopy n= du 71 both treatment HP Confirm cured when eradication bacterial culture, urease test, and 1-2 months after tx urea breath test all negative Breath test and f/u endoscopy performed : 619pts, 2 wk dual therapy to determine HP status (amox 750 bid/ppi bid) : 670 pts, 1wk triple tx n=1120 endoscopy and urea (amox 750 bid/clarith 200mg or completed >/= 1 year breath tests yearly 400mg bid) : 53 pts, 1wk metronidazole 500 bid, amox 750 bid, or clarithro followed for up mg bid and ppi bid years (mean 3.4y) Take S. et al. Am J Gastroenterol 2005;100:

20 Slide 58 evaluate ulcers, background gastric mucosa, HP infection All gastric cancer in patients with GU, none in DU (p=0.005) Methods Index endoscopy n= gu 495 du 71 both Confirm eradication n=1120 completed >/= 1 year n=176 persistent infection n=4 Gastric cancer n=944 cured of infection n=8 Gastric cancer Take S. et al. Am J Gastroenterol 2005;100: Slide 59 Risk of developing gastric cancer in patients cured of infection vs. persistent infection was significantly lower 1.21% vs. 3.80% at 5 yrs (p=0.04) patients with PUD 2.00% vs. 6.41% at 5 yrs (p=0.04 ) patients with GU Take S. et al. Am J Gastroenterol 2005;100: Slide 60 persistent infection was the most significant risk factor for gastric ca H. pylori eradication may reduce risk of gastric cancer Is eradication enough? Take S. et al. Am J Gastroenterol 2005;100:

21 Slide 61 Compelling reason # 2 ERADICATION IS NOT ENOUGH Aim: (1) identify risk factors for progression of gastric IM (2) identify high risk subgroup that might warrant intensive surveillance University of China Hong Kong Volunteers residing in Yantai county of Shandong invited for screening endoscopy Randomized control study over 5 years. HP(+) patients received either anti-hp therapy or placebo Leung WK et al. Gut 2004;53: Slide 62 n=295 1 week tx n= 587 HP (+) Index endoscopy n=292 placebo 152 LTFU n=220 f/u endoscopy n=215 5 year analysis n=164 HP clearance n=20 (74.5%) confirmed by histology (9.3%) All completed the 2 endoscopies or found gastric cancer within the 5 year f/u n=4 cancers H. pylori infection= both rapid urease and histology positive 10 (2.3%) developed n=6 cancers invasive gastric ca during f/u Progression of IM = higher score at five years compared with baseline Leung WK et al. Gut 2004;53: Slide 63 Results Eradication of HP infection significantly retards but does not eliminate IM progression 52.9% had progression of IM over 5 years Conclusions: Identified a subgroup (age + persistent HPI) at high risk of progression that may warrant more intensive endoscopic surveillance Leung WK et al. Gut 2004;53:

22 Slide 64 Compelling reason # 3 EVIDENCE OF UTILITY Example of Japan 1986: Case control study in farm village, Osaka - screening since 1962 OR of death from stomach cancer in screened vs. unscreened was males / OR females Effective in reducing stomach cancer mortality by half 1988: prospective cohort study incidence rate same RR diagnosing advanced stomach cancer Effective in reducing mortality from stomach cancer Prospective study over 13 year f/u in Japan involving patients 2 fold decrease in mortality in screened vs. unscreened patients (RR=0.52;95%CI ) Significant decrease in incidence of advanced gastric cancer in screened subjects (RR = 0.75;95% CI= ) Oshima A et al. Int J Cancer 1986:38: Hisamichi S et al. Cancer Detec Prev 1988:11: Lee, KJ et al. Int J Cancer 2006:118; Slide 65 Compelling reason # 4 EVIDENCE OF UTILITY EXTENDS BEYOND ASIA Aim: to determine the incidence of gastric cancers in this high risk (IM, ulcers, polyps) group and to evaluate the potential for early diagnosis and treatment Dyspepsia clinics in area of the Queen Elizabeth and Sandwell District General Hospital, Patients over age 40 referred to dyspepsia clinic Whiting JL et al. Gut 2002;50: Slide 66 Methods n=1753 OAE n=22 (1.3%) gastric cancer Requiring followup: dysplasia, IM, AG, foveolar hyperplasia, regenerative changes, polyps, ulcers n=368 (21%) offered surveillance lesions requiring f/u endoscopy n=166 annual endoscopy accepted ulcers re-examined q2mo until healing n=14 cancers (8.4%) 10 years follow-up Whiting JL et al. Gut 2002;50:

23 Slide 67 Results More cancers detected from surveillance were of an earlier stage than those detected at open access 5year survival was significantly higher than tumors detected at open access stage I /II 67% vs. 23%; p< % vs. 10%; p=0.006 * Conclude: In patients with IM, annual surveillance can detect most new tumors at early stage with major improvement in survival Whiting JL et al. Gut 2002;50: Slide 68 Compelling reason # 5 PERSPECTIVE ON THE BURDEN OF DISEASE For example: We screen for Barretts and then do surveillance for esophageal cancer United states 5.8 (gastric cancer 5.7) Esophageal vs. gastric cancer Burden of disease Esophageal vs. gastric cancer Incidence of disease after detection of premalignant lesions Globocan 2008: cancer incidence, mortality and prevalence worldwide. IARC Cancer Base No. 5 version 2.0, IARC Press 2008 Take S. et al. Am J Gastroenterol 2005;100: Slide 69 we BE is a strong risk factor for esophageal adenocarcinoma Annual risk = 0.12% (lower than assumed 0.5%) HP(+) is a strong risk factor for gastric adenocarcinoma Annual risk = is 0.37% Risk is increased to 0.26% when high grade dysplasia included Risk is 0.5%/year HP (+) 0.24%/yr HP eradication Hvid-Jensen et al. N Engl J Med 2011;365: Uemura N et al. N Engl J Med 2001;345:784-9 Leung WK et al. Gut 2004;53:

24 Invasiveness Gastric cancer risk Slide 70 UNANSWERED ASGE Guidelines QUESTIONS Benefits of surveillance has been evaluated and known How H. pylori and should who be should treated be if found tested for H. pylori? What If low grade could dysplasia be done is detected, before dysplasia? surveillance EGD with topographic at the point mapping of intestinal metaplasia Who For US, is the considered progression higher of IM to than cancer average is low and risk? surveillance is not indicated for the average risk patient ASGE guideline: the role of endoscopy in the surveillance of premalignant conditions of the upper GI tract. GIE 2006;63: Slide 71 Proposed Strategy for Screening and Surveillance for low prevalence regions Epidemiologic Risk Factors Identify population for noninvasive screening Serologic Screening Histologic Evaluation Endoscopic Surveillance HP eradication? Identify premalignant lesions at risk of progression Early tx dysplasia de Vries AC et al. Helicobacter2007;12:1-15 Slide 72 Intestinal metaplasia MANAGEMENT ALGORITHM Yes Assess HP, treat If if biopsies (+) negative for HP noninvasive testing Extensive or incomplete IM Unknown No Surveillance EGD High risk patient? High risk patient? mapping q2-3yrs yes no yes no Characterize: histologic subtype (complete Repeat vsegd incomplete) Individualize : extent (limited vs. extensive) mapping in 3 yrs repeat EGD mapping determine the risk of malignancy and guide surveillance High risk patient: Individualize : No surveillance Family history gastric ca surveillance EGD Noncaucasian: african american, hispanic, asian Immigrant : east asia or mountainous latin america Correa P. et al. Am J Gastro 2010;105:493 Dinis-ribeiro M. et al. Endoscopy 2012;44:74-94

25 Slide 73 The discrepancy H. pylori is a carcinogen We do not screen for it IM is a premalignant state We do not offer surveillance The United states is a diverse place We do not individualize risk factors Slide 74 How do we change? Identify Treat Test Eradicate Slide 75 How do we change? Family history gastric cancer Refractory gastric ulcers Refractory H. pylori infection Abnormal gastric histology: Intestinal metaplasia Atrophic gastritis Autoimmune gastritis Hyperplasia/hyperplastic polyps Adenomatous polyps Regenerative changes Carcinoids

26 Known Unknown Unknown Slide 76 How do we change? Benefit Low prevalence places High risk populations amongst low prevalence places Slide 77 Take Home Points Patients at risk for developing gastric cancer can be identified by ethnicity, country of origin, HP status HP screening and eradication may reduce the risk of gastric cancer Surveillance of high risk lesions may increase detection of early stage gastric cancer and therefore reduce mortality Given inherent diversity of the US, there may not be a true average risk patient risk assessment needs to be individualized There is a role for targeted screening and surveillance for gastric cancer amongst high risk populations within a traditionally low risk region Slide 78 Questions? THANK YOU!

Helicobacter pylori: Diagnosis, treatment and risks of untreated infection

Helicobacter pylori: Diagnosis, treatment and risks of untreated infection Helicobacter pylori: Diagnosis, treatment and risks of untreated infection Klaus Mönkemüller Department of Gastroenterology, Hepatology und Infectius Diseases Otto-von-Guericke University, Magdeburg bb

More information

Helicobacter Pylori Testing HELICOBACTER PYLORI TESTING HS-131. Policy Number: HS-131. Original Effective Date: 9/17/2009

Helicobacter Pylori Testing HELICOBACTER PYLORI TESTING HS-131. Policy Number: HS-131. Original Effective Date: 9/17/2009 Easy Choice Health Plan, Inc. Harmony Health Plan of Illinois, Inc. Missouri Care, Inc. Ohana Health Plan, a plan offered by WellCare Health Insurance of Arizona, Inc. WellCare Health Insurance of Illinois,

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: helicobacter_pylori_testing 01/01/2019 N/A 01/01/2020 01/01/2019 Policy Effective April 1, 2019 Description

More information

Helicobacter 2008;13:1-6. Am J Gastroent 2007;102: Am J of Med 2004;117:31-35.

Helicobacter 2008;13:1-6. Am J Gastroent 2007;102: Am J of Med 2004;117:31-35. An Update on Helicobacter pylori and Its Treatment Trenika Mitchell, PharmD, BCPS Clinical Assistant Professor University of Kentucky College of Pharmacy October 18, 2008 Objectives Review the epidemiology

More information

Disclosures. Gastric Intestinal Metaplasia and Early Gastric Cancer: Screening, Surveillance, and Endoscopic Therapy. ASGE Guidelines.

Disclosures. Gastric Intestinal Metaplasia and Early Gastric Cancer: Screening, Surveillance, and Endoscopic Therapy. ASGE Guidelines. Gastric Intestinal Metaplasia and Early Gastric Cancer: Screening, Surveillance, and Endoscopic Therapy Consultant for: Olympus Medtronic US Endoscopy Disclosures Joo Ha Hwang, MD, PhD Associate Professor

More information

Management of dyspepsia and of Helicobacter pylori infection

Management of dyspepsia and of Helicobacter pylori infection Management of dyspepsia and of Helicobacter pylori infection The University of Nottingham John Atherton Wolfson Digestive Diseases Centre University of Nottingham, UK Community management of dyspepsia

More information

What is the status of Sequential Therapy Versus Standard Triple- Drug Therapy in peptic ulcer disease in eradicating H pylori?

What is the status of Sequential Therapy Versus Standard Triple- Drug Therapy in peptic ulcer disease in eradicating H pylori? What is the status of Sequential Therapy Versus Standard Triple- Drug Therapy in peptic ulcer disease in eradicating H pylori? Sequential Therapy Versus Standard Triple- Drug Therapy for Helicobacter pylori

More information

Association of Helicobacter pylori infection with Atrophic gastritis in patients with Dyspepsia

Association of Helicobacter pylori infection with Atrophic gastritis in patients with Dyspepsia ADVANCES IN BIORESEARCH Adv. Biores., Vol 8 [3] May 2017: 137-141 2017 Society of Education, India Print ISSN 0976-4585; Online ISSN 2277-1573 Journal s URL:http://www.soeagra.com/abr.html CODEN: ABRDC3

More information

Acid-Peptic Diseases of the Stomach and Duodenum Including Helicobacter pylori and NSAIDs Prof. Sheila Crowe

Acid-Peptic Diseases of the Stomach and Duodenum Including Helicobacter pylori and NSAIDs Prof. Sheila Crowe Acid-Peptic Diseases of the Stomach and Duodenum Including Helicobacter pylori and NSAIDs 1 Division of Gastroenterology UC San Diego School of Medicine Clinical presentations of Helicobacter pylori infection

More information

Treatment of Helicobacter pylori Infection

Treatment of Helicobacter pylori Infection Treatment of Helicobacter pylori Infection Epidemiology of H. pylori infection (North America) Which are the high risk groups? Epidemiology of H. pylori infection (North America) Which are the high risk

More information

American College of Gastroenterology Guideline on the Management of Helicobacter pylori Infection

American College of Gastroenterology Guideline on the Management of Helicobacter pylori Infection American Journal of Gastroenterology ISSN 0002-9270 C 2007 by Am. Coll. of Gastroenterology doi: 10.1111/j.1572-0241.2007.01393.x Published by Blackwell Publishing American College of Gastroenterology

More information

Safety Of. long-term PPI. Layli Eslami, MD Tehran, 1393

Safety Of. long-term PPI. Layli Eslami, MD Tehran, 1393 Safety Of long-term PPI Layli Eslami, MD Tehran, 1393 n The introduction of PPIs in the late 1980s optimized the medical treatment of acidrelated disorders n In some cases such as GERD patients given the

More information

Endoscopic atrophic classification before and after H. pylori eradication is closely associated with histological atrophy and intestinal metaplasia

Endoscopic atrophic classification before and after H. pylori eradication is closely associated with histological atrophy and intestinal metaplasia E311 before and after H. pylori eradication is closely associated with histological atrophy and intestinal metaplasia Authors Institution Masaaki Kodama, Tadayoshi Okimoto, Ryo Ogawa, Kazuhiro Mizukami,

More information

Proton Pump Inhibitors Drug Class Prior Authorization Protocol

Proton Pump Inhibitors Drug Class Prior Authorization Protocol Proton Pump Inhibitors Drug Class Prior Authorization Protocol Line of Business: Medi-Cal P&T Approval Date: November 15, 2017 Effective Date: January 1, 2018 This policy has been developed through review

More information

PEPTIC ULCER DISEASE JOHN R SALTZMAN, MD. Director of Endoscopy Brigham and Women s Hospital Professor of Medicine Harvard Medical School

PEPTIC ULCER DISEASE JOHN R SALTZMAN, MD. Director of Endoscopy Brigham and Women s Hospital Professor of Medicine Harvard Medical School PEPTIC ULCER DISEASE JOHN R SALTZMAN, MD Director of Endoscopy Brigham and Women s Hospital Professor of Medicine Harvard Medical School No disclosures Disclosures Overview Causes of peptic ulcer disease

More information

COMPARISON OF ONCE-A-DAY VERSUS TWICE-A-DAY CLARITHROMYCIN IN TRIPLE THERAPY FOR HELICOBACTER PYLORI ERADICATION

COMPARISON OF ONCE-A-DAY VERSUS TWICE-A-DAY CLARITHROMYCIN IN TRIPLE THERAPY FOR HELICOBACTER PYLORI ERADICATION Phil J Gastroenterol 2006; 2: 25-29 COMPARISON OF ONCE-A-DAY VERSUS TWICE-A-DAY CLARITHROMYCIN IN TRIPLE THERAPY FOR HELICOBACTER PYLORI ERADICATION Marianne P Collado, Ma Fatima P Calida, Peter P Sy,

More information

Maastricht Ⅴ /Florence

Maastricht Ⅴ /Florence 2016 21 10 577 Maastricht Ⅴ /Florence 200001 2015 10 8 9 Maastricht V 1 / 2 3 4 / 5 Maastricht Ⅴ Interpretation of Management of Helicobacter pylori Infection the Maastricht Ⅴ / Florence Consensus Report

More information

DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT OF DYSPEPSIA

DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT OF DYSPEPSIA DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT OF DYSPEPSIA o Patients of any age with ALARM signs should be referred through the 2-week referral system o Routine endoscopic investigation

More information

ACG Clinical Guideline: Treatment of Helicobacter pylori Infection

ACG Clinical Guideline: Treatment of Helicobacter pylori Infection ACG Clinical Guideline: Treatment of Helicobacter pylori Infection William D. Chey, MD, FACG 1, Grigorios I. Leontiadis, MD, PhD 2, Colin W. Howden, MD, FACG 3 and Steven F. Moss, MD, FACG 4 1 Division

More information

Disclosures. Co-founder and Chief Science Officer, TechLab

Disclosures. Co-founder and Chief Science Officer, TechLab H. pylori testing Disclosures Co-founder and Chief Science Officer, TechLab Learning Objectives Evaluate the appropriate testing methodology by balancing performance, economics, and workflow. Discuss the

More information

Disclosures. GI Motility Disorders. Gastrointestinal Motility Disorders & Irritable Bowel Syndrome

Disclosures. GI Motility Disorders. Gastrointestinal Motility Disorders & Irritable Bowel Syndrome Gastrointestinal Motility Disorders & Irritable Bowel Syndrome None Disclosures Jasmine Zia, MD Acting Assistant Professor Division of Gastroenterology, University of Washington 6 th Asian Health Symposium

More information

Introduction. Original articles. Nicolás Rocha, 1 Sandra Huertas, 2 Rosario Albis, 3 Diego Aponte, 4 Luis Carlos Sabbagh. 5

Introduction. Original articles. Nicolás Rocha, 1 Sandra Huertas, 2 Rosario Albis, 3 Diego Aponte, 4 Luis Carlos Sabbagh. 5 Original articles Correlation of endoscopic and histological findings in diagnosis of gastrointestinal metaplasia in patients referred to the Clinica Colombia for upper endoscopies Nicolás Rocha, 1 Sandra

More information

6/25/ % 20% 50% 19% Functional Dyspepsia Peptic Ulcer GERD Cancer Other

6/25/ % 20% 50% 19% Functional Dyspepsia Peptic Ulcer GERD Cancer Other Peptic Ulcer Disease and Dyspepsia John M. Inadomi, MD Professor of Medicine UCSF Chief, Clinical Gastroenterology San Francisco General Hospital Case History 49 y/o woman complains of several months of

More information

I. Kalfus MD, D. Riff MD, R. Fathi PhD, D. Graham MD

I. Kalfus MD, D. Riff MD, R. Fathi PhD, D. Graham MD A Randomized Double Blind Placebo Controlled Phase III Study to Assess the Safety and Efficacy of Rifabutin Triple Therapy (RHB-105) for Helicobacter pylori (H. pylori) Infection in Dyspepsia Patients

More information

Helicobacter pylori 幽門螺旋桿菌 馬偕紀念醫院新竹分院一般內科, 肝膽腸胃科陳重助醫師

Helicobacter pylori 幽門螺旋桿菌 馬偕紀念醫院新竹分院一般內科, 肝膽腸胃科陳重助醫師 Helicobacter pylori 幽門螺旋桿菌 馬偕紀念醫院新竹分院一般內科, 肝膽腸胃科陳重助醫師 Hp : Helicobacter pylori Part 1. Pathophysiology and immune response Pathogenesis of Hp infection Part 2. Clinical manifestation Part 3. Dx tests for

More information

Treating H. pylori in 2016

Treating H. pylori in 2016 Treating H. pylori in 2016 William D. Chey, MD, FACG Professor of Medicine University of Michigan The Case: A 38 yo Russian man presents with recurrent epigastric pain which occurs after meals and sometimes

More information

Urea Breath Test for Diagnosis of Helicobactor pylori. Original Policy Date 12:2013

Urea Breath Test for Diagnosis of Helicobactor pylori. Original Policy Date 12:2013 MP 2.04.04 Urea Breath Test for Diagnosis of Helicobactor pylori Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date 12:2013 Return to Medical Policy Index

More information

Peptic Ulcer Disease Update

Peptic Ulcer Disease Update Peptic Ulcer Disease Update Col Pat Storms RAM 2005 Disclosure Information 84th Annual AsMA Scientific Meeting Col Patrick Storms I have no financial relationships to disclose. I will discuss the following

More information

Updates in Evaluation and Management of Dyspepsia and H. Pylori Infection

Updates in Evaluation and Management of Dyspepsia and H. Pylori Infection Updates in Evaluation and Management of Dyspepsia and H. Pylori Infection Isabel Lee, MD Associate Professor of Health Sciences UCSF Department of Family and Community Medicine Disclosures None 2 Session

More information

GI update. Common conditions and concerns my patients frequently asked about

GI update. Common conditions and concerns my patients frequently asked about GI update Common conditions and concerns my patients frequently asked about Specific conditions I ll try to cover today 1. Colon polyps, colorectal cancer and colonoscopy 2. Crohn s disease 3. Peptic ulcer

More information

11/19/2012. Comparison between PPIs G CELL. Risk ratio (95% CI) Patient subgroup. gastrin. S-form of omeprazole. Acid sensitive. coated.

11/19/2012. Comparison between PPIs G CELL. Risk ratio (95% CI) Patient subgroup. gastrin. S-form of omeprazole. Acid sensitive. coated. REGULATION OF GASTRIC ACID SECRETION Comparison between PPIs Omeprazole Lansoprazole Rabeprazole Pantoprazole Esomeprazole gastrin G CELL + Acid sensitive Yes T1/2 30-60 minutes Main elimination Enteric

More information

Comparative study of invasive methods for diagnosis of Helicobacter pylori in humans

Comparative study of invasive methods for diagnosis of Helicobacter pylori in humans ISSN: 2319-7706 Volume 2 Number 7 (2013) pp. 63-68 http://www.ijcmas.com Original Research Article Comparative study of invasive methods for diagnosis of Helicobacter pylori in humans V.Subbukesavaraja

More information

Helicobacter pylori Improved Detection of Helicobacter pylori

Helicobacter pylori Improved Detection of Helicobacter pylori DOI:http://dx.doi.org/10.7314/APJCP.2016.17.4.2099 RESEARCH ARTICLE Improved Detection of Helicobacter pylori Infection and Premalignant Gastric Mucosa Using Conventional White Light Source Gastroscopy

More information

Helicobacter Connections. Barry Marshall

Helicobacter Connections. Barry Marshall Helicobacter Connections Barry Marshall The greatest obstacle to knowledge is not ignorance, it is the illusion of knowledge. Daniel Boorstein - Historian Peptic Ulcers Duodenal Ulcer (DU) Gastric Ulcer

More information

Table 2.9. Case control studies of helicobacter pylori infection and oesophageal adenocarcinoma

Table 2.9. Case control studies of helicobacter pylori infection and oesophageal adenocarcinoma Characteristics of Characteristics of controls Detection Chow et al (1998) 1993-1995 129 of newly diagnosed oesophageal/gastric cardia (OGC) adenocarcinoma. 224 population controls selected by random digit

More information

Barrett s Esophagus. Abdul Sami Khan, M.D. Gastroenterologist Aurora Healthcare Burlington, Elkhorn, Lake Geneva, WI

Barrett s Esophagus. Abdul Sami Khan, M.D. Gastroenterologist Aurora Healthcare Burlington, Elkhorn, Lake Geneva, WI Barrett s Esophagus Abdul Sami Khan, M.D. Gastroenterologist Aurora Healthcare Burlington, Elkhorn, Lake Geneva, WI A 58 year-old, obese white man has had heartburn for more than 20 years. He read a magazine

More information

Clinical Policy Title: Noninvasive testing for H. pylori

Clinical Policy Title: Noninvasive testing for H. pylori Clinical Policy Title: Noninvasive testing for H. pylori Clinical Policy Number: 08.01.05 Effective Date: January 1, 2016 Initial Review Date: August 19, 2015 Most Recent Review Date: August 17, 2017 Next

More information

Clinical Policy Title: Noninvasive testing for H. pylori

Clinical Policy Title: Noninvasive testing for H. pylori Clinical Policy Title: Noninvasive testing for H. pylori Clinical Policy Number: 08.01.04 Effective Date: January 1, 2016 Initial Review Date: August 19, 2015 Most Recent Review Date: August 17, 2016 Next

More information

Gastric Polyps. Bible class

Gastric Polyps. Bible class Gastric Polyps Bible class 29.08.2018 Starting my training in gastroenterology, some decades ago, my first chief always told me that colonoscopy may seem technically more challenging but gastroscopy has

More information

Viral hepatitis and Hepatocellular Carcinoma

Viral hepatitis and Hepatocellular Carcinoma Viral hepatitis and Hepatocellular Carcinoma Hashem B. El-Serag, MD, MPH Dan L. Duncan Professor of Medicine Chief, Gastroenterology and Hepatology Houston VA & Baylor College of Medicine Houston, TX Outline

More information

PDF hosted at the Radboud Repository of the Radboud University Nijmegen

PDF hosted at the Radboud Repository of the Radboud University Nijmegen PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/48400

More information

National Digestive Diseases Information Clearinghouse

National Digestive Diseases Information Clearinghouse Gastritis National Digestive Diseases Information Clearinghouse U.S. Department of Health and Human Services NATIONAL INSTITUTES OF HEALTH What is gastritis? Gastritis is a condition in which the stomach

More information

Update on the pathological classification of gastritis. Hala El-Zimaity, M.D. M.S. Epidemiology McMaster University Hamilton, Ontario Canada

Update on the pathological classification of gastritis. Hala El-Zimaity, M.D. M.S. Epidemiology McMaster University Hamilton, Ontario Canada Update on the pathological classification of gastritis Hala El-Zimaity, M.D. M.S. Epidemiology McMaster University Hamilton, Ontario Canada CLASSIFICATION GASTRITIS GASTROPATHY 1. Acute 2. Chronic 3. Uncommon

More information

Clinical Policy Title: Noninvasive testing for H. pylori

Clinical Policy Title: Noninvasive testing for H. pylori Clinical Policy Title: Noninvasive testing for H. pylori Clinical Policy Number: 08.01.04 Effective Date: January 1, 2016 Initial Review Date: August 19, 2015 Most Recent Review Date: August 17, 2016 Next

More information

June By: Reza Gholami

June By: Reza Gholami ACG/CAG guideline on Management of Dyspepsia June 2017 By: Reza Gholami DEFINITION OF DYSPEPSIA AND SCOPE OF THE GUIDELINE Dyspepsia was originally defined as any symptoms referable to the upper gastrointestinal

More information

Clinical Policy Title: Breath Testing for H. Pylori

Clinical Policy Title: Breath Testing for H. Pylori Clinical Policy Title: Breath Testing for H. Pylori Clinical Policy Number: 08.01.04 Effective Date: January 1, 2016 Initial Review Date: August 19, 2015 Most Recent Review Date: August 19, 2015 Next Review

More information

MEDICAL POLICY EFFECTIVE DATE: 05/19/11 REVISED DATE: 05/24/12, 05/23/13 ARCHIVED DATE: 05/22/14 EDITED DATE: 05/28/15, 05/25/16, 05/18/17, 05/17/18

MEDICAL POLICY EFFECTIVE DATE: 05/19/11 REVISED DATE: 05/24/12, 05/23/13 ARCHIVED DATE: 05/22/14 EDITED DATE: 05/28/15, 05/25/16, 05/18/17, 05/17/18 MEDICAL POLICY SUBJECT: NON-INVASIVE HELICOBACTER PAGE: 1 OF: 6 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product, including

More information

Research Article Performance of Routine Helicobacter pylori Invasive Tests in Patients with Dyspepsia

Research Article Performance of Routine Helicobacter pylori Invasive Tests in Patients with Dyspepsia Gastroenterology Research and Practice Volume 2013, Article ID 184806, 5 pages http://dx.doi.org/10.1155/2013/184806 Research Article Performance of Routine Helicobacter pylori Invasive Tests in Patients

More information

Fecoprevalence and determinants of Helicobacter pylor infection among asymptomatic children in Myanmar

Fecoprevalence and determinants of Helicobacter pylor infection among asymptomatic children in Myanmar International Journal of Gastroenterology, Hepatology, Transplant & Nutrition Original Article Fecoprevalence and determinants of Helicobacter pylor infection among asymptomatic children in Myanmar Hnin

More information

Management of Dyspepsia

Management of Dyspepsia MPharm Programme Management of Dyspepsia Slide 1 of 28 Learning Objectives Understand the principles and wider implications underpinning evidence based therapeutics in the key clinical specialities Objectively

More information

Clinical Policy: Helicobacter Pylori Serology Testing Reference Number: CP.MP.153

Clinical Policy: Helicobacter Pylori Serology Testing Reference Number: CP.MP.153 Clinical Policy: Reference Number: CP.MP.153 Effective Date: 12/17 Last Review Date: 12/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory and

More information

Is there a role for screening gastric carcinoma or preneoplastic lesions?

Is there a role for screening gastric carcinoma or preneoplastic lesions? Is there a role for screening gastric carcinoma or preneoplastic lesions? Mário Dinis-Ribeiro, MD, PhD Instituto Português de Oncologia do Porto, Department of Gastroenterology Faculty of Medicine, University

More information

Intragastric Acidification Reduces the Occurrence of False-Negative Urea Breath Test Results in Patients Taking a Proton Pump Inhibitor

Intragastric Acidification Reduces the Occurrence of False-Negative Urea Breath Test Results in Patients Taking a Proton Pump Inhibitor THE AMERICAN JOURNAL OF GASTROENTEROLOGY Vol. 96, No. 4, 2001 2001 by Am. Coll. of Gastroenterology ISSN 0002-9270/01/$20.00 Published by Elsevier Science Inc. PII S0002-9270(01)02250-X Intragastric Acidification

More information

HELICOBACTER PYLORI ERADICATION TREATMENT AND THE RISK OF GASTRIC AND OESOPHAGEAL CANCER

HELICOBACTER PYLORI ERADICATION TREATMENT AND THE RISK OF GASTRIC AND OESOPHAGEAL CANCER From the Department of Molecular Medicine and Surgery Karolinska Institutet, Stockholm, Sweden HELICOBACTER PYLORI ERADICATION TREATMENT AND THE RISK OF GASTRIC AND OESOPHAGEAL CANCER Eva Doorakkers Stockholm

More information

Unexpected Findings at Endoscopy

Unexpected Findings at Endoscopy The Endoscopic Incidentaloma: What to Tell Your Patient t with Unexpected Endoscopic Findings: Gastric Intestinal Metaplasia, Silent Ileitis, Carcinoid David Greenwald, MD Montefiore Medical Center Albert

More information

Epidemiology of Peptic Ulcer Disease

Epidemiology of Peptic Ulcer Disease Epidemiology of Peptic Ulcer Disease Introduction Peptic Ulcer Disease (PUD) is disruption of the mucosal integrity of the stomach and/or duodenum leading to a local defect or excavation due to active

More information

MANAGEMENT OF DYSPEPSIA AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)

MANAGEMENT OF DYSPEPSIA AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT OF DYSPEPSIA AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) Routine endoscopic investigation of patients of any age, presenting with dyspepsia

More information

Evaluation of a new rapid immunoassay for the detection of Helicobacter pylori in faeces: a prospective pilot study

Evaluation of a new rapid immunoassay for the detection of Helicobacter pylori in faeces: a prospective pilot study Aliment Pharmacol Ther 2005; 21: 485 489. doi: 10.1111/j.1365-2036.2005.02355.x Evaluation of a new rapid immunoassay for the detection of Helicobacter pylori in faeces: a prospective pilot study L. TREVISANI*,

More information

Ethnic Distribution of Atrophic Autoimmune Gastritis in the United States

Ethnic Distribution of Atrophic Autoimmune Gastritis in the United States Ethnic Distribution of Atrophic Autoimmune Gastritis in the United States Robert M. Genta, Regan Allen, Massimo Rugge Miraca Life Sciences Research Institute, Miraca Life Sciences, Irving, Texas UTSW University

More information

Type of intervention Diagnosis. Economic study type Cost-effectiveness analysis.

Type of intervention Diagnosis. Economic study type Cost-effectiveness analysis. Noninvasive tests as a substitute for histology in the diagnosis of Helicobacter pylori infection Hahn M, Fennerty M B, Corless C L, Magaret N, Lieberman D A, Faigel D O Record Status This is a critical

More information

Barrett esophagus. Bible class Inselspital

Barrett esophagus. Bible class Inselspital Barrett esophagus Bible class Inselspital 2015.08.10 Guidelines Definition? BSG: ACG: Definition? BSG: ACG: What are the arguments for and against IM as prerequisite for the Dg? What are the arguments

More information

Korean gastric cancer screening program, algorithms and experience.

Korean gastric cancer screening program, algorithms and experience. Korean gastric cancer screening program, algorithms and experience. Jun Haeng Lee, MD. Department of Medicine, Sungkyunkwan University School of Medicine, Seoul, Korea Today s topics Korean cancer screening

More information

Helicobacter and gastritis

Helicobacter and gastritis 1 Helicobacter and gastritis Dr. Hala Al Daghistani Helicobacter pylori is a spiral-shaped gram-negative rod. H. pylori is associated with antral gastritis, duodenal (peptic) ulcer disease, gastric ulcers,

More information

Barrett s Esophagus: Old Dog, New Tricks

Barrett s Esophagus: Old Dog, New Tricks Barrett s Esophagus: Old Dog, New Tricks Stuart Jon Spechler, M.D. Chief, Division of Gastroenterology, VA North Texas Healthcare System; Co-Director, Esophageal Diseases Center, Professor of Medicine,

More information

Everything Esophagus: Barrett s Esophagus. Nicholas Shaheen, MD, MPH Center for Esophageal Diseases and Swallowing University of North Carolina

Everything Esophagus: Barrett s Esophagus. Nicholas Shaheen, MD, MPH Center for Esophageal Diseases and Swallowing University of North Carolina Everything Esophagus: Barrett s Esophagus Nicholas Shaheen, MD, MPH Center for Esophageal Diseases and Swallowing University of North Carolina The Most Important Thing Stayed the Same Adenocarcinoma A

More information

CHAPTER 18. PEPTIC ULCER DISEASE, SELF-ASSESSMENT QUESTIONS. 1. Which of the following is not a common cause of peptic ulcer disease (PUD)?

CHAPTER 18. PEPTIC ULCER DISEASE, SELF-ASSESSMENT QUESTIONS. 1. Which of the following is not a common cause of peptic ulcer disease (PUD)? CHAPTER 18. PEPTIC ULCER DISEASE, SELF-ASSESSMENT QUESTIONS 1. Which of the following is not a common cause of peptic ulcer disease (PUD)? A. Chronic alcohol ingestion B. Nonsteroidal antiinflammatory

More information

A Trip Through the GI Tract: Common GI Diseases and Complaints. Jennifer Curtis, MD

A Trip Through the GI Tract: Common GI Diseases and Complaints. Jennifer Curtis, MD A Trip Through the GI Tract: Common GI Diseases and Complaints Jennifer Curtis, MD Colon Cancer How does it develop? Most cancers arise from polyps Over time these can turn into cancer Combination of genetic

More information

Correlation Between Endoscopic and Histological Findings in Different Gastroduodenal Lesion and its Association with Helicobacter Pylori

Correlation Between Endoscopic and Histological Findings in Different Gastroduodenal Lesion and its Association with Helicobacter Pylori ORIGINAL ARTICLE Correlation Between Endoscopic and Histological Findings in Different Gastroduodenal Lesion and its Association with Helicobacter Pylori *A. Sultana 1, SM Badruddoza 2, F Rahman 3 1 Dr.

More information

The PPI Doesn t Work, Now What? PPI Non-responsive Dyspepsia. Disclosures

The PPI Doesn t Work, Now What? PPI Non-responsive Dyspepsia. Disclosures The PPI Doesn t Work, Now What? PPI Non-responsive Dyspepsia Lana Bistritz MD FRCPC Royal Alexandra Hospital GI Update 2016 Disclosures I have no relevant financial disclosures I will be discussing off

More information

TRANSPARENCY COMMITTEE OPINION. 13 December 2006

TRANSPARENCY COMMITTEE OPINION. 13 December 2006 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 13 December 2006 HELIKIT 75 mg, powder for oral solution CIP : 343 132-1 Applicant : MAYOLY SPINDLER 13 Curea anhydrous

More information

GI Pearls and Diagnostic Errors

GI Pearls and Diagnostic Errors GI Pearls and Diagnostic Errors David A. Johnson MD MACG FASGE FACP Professor of Medicine Chief of Gastroenterology Eastern VA Medical School Norfolk VA Disclosures Editor: NEJM J Watch Gastro (esophageal)

More information

594 Lewin, Weinstein, and Riddell s Gastrointestinal Pathology and Its Clinical Implications

594 Lewin, Weinstein, and Riddell s Gastrointestinal Pathology and Its Clinical Implications 594 Lewin, Weinstein, and Riddell s Gastrointestinal Pathology and Its Clinical Implications Figure 13-20. Stages in the natural history of H. pylori. Biopsies from the antrum are on the left and the oxyntic

More information

Gastrointestinal pathology 2018 lecture 4. Dr Heyam Awad FRCPath

Gastrointestinal pathology 2018 lecture 4. Dr Heyam Awad FRCPath Gastrointestinal pathology 2018 lecture 4 Dr Heyam Awad FRCPath Topics to be covered Peptic ulcer disease Hiatal hernia Gastric neoplasms Peptic ulcer disease (PUD)= chronic gastric ulcer Causes H pylori

More information

Gastrointestinal Tract Cancer

Gastrointestinal Tract Cancer Gastrointestinal Tract Cancer Tumors of the Stomach Gastric adenocarcinoma Incidence and Epidemiology Incidence mortality rates USA High incidence: Japan, China, Chile, Ireland risk lower socioeconomic

More information

GASTROINTESTINAL AND ANTIEMETIC DRUGS. Submitted by: Shaema M. Ali

GASTROINTESTINAL AND ANTIEMETIC DRUGS. Submitted by: Shaema M. Ali GASTROINTESTINAL AND ANTIEMETIC DRUGS Submitted by: Shaema M. Ali GASTROINTESTINAL AND ANTIEMETIC DRUGS by: Shaema M. Ali There are four common medical conditions involving the GI system 1) peptic ulcers

More information

Outline. Definition (s) Epidemiology Pathophysiology Management With an emphasis on recent developments

Outline. Definition (s) Epidemiology Pathophysiology Management With an emphasis on recent developments Chronic Dyspepsia Eamonn M M Quigley MD FRCP FACP MACG FRCPI Lynda K and David M Underwood Center for Digestive Disorders Houston Methodist Hospital Houston, Texas Outline Definition (s) Epidemiology Pathophysiology

More information

1. Appropriateness of Gastroscopy: Dyspepsia 1

1. Appropriateness of Gastroscopy: Dyspepsia 1 Special Topic 579 1. Appropriateness of Gastroscopy: Dyspepsia 1 F. Froehlich *, M. Bochud **, J.-J. Gonvers*, R.W. Dubois***, J.-P. Vader **, V. Wietlisbach ***, B. Burnand ** * Policlinique Médicale

More information

EDUCATION PRACTICE. Persistent Helicobacter pylori Infection After a Course of Antimicrobial Therapy What s Next? Clinical Scenario.

EDUCATION PRACTICE. Persistent Helicobacter pylori Infection After a Course of Antimicrobial Therapy What s Next? Clinical Scenario. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2008;6:1086 1090 EDUCATION PRACTICE Persistent Helicobacter pylori Infection After a Course of Antimicrobial Therapy What s Next? RICHARD J. SAAD* and WILLIAM D.

More information

Helicobacter Pylori: Treatment Rates and Strategies for Improvement in a Community Health Center Population

Helicobacter Pylori: Treatment Rates and Strategies for Improvement in a Community Health Center Population Eileen Condon October 28, 2011 SEARCH Program Abstract Background Helicobacter Pylori: Treatment Rates and Strategies for Improvement in a Community Health Center Population Gastric cancer is a major global

More information

Management of Barrett s Esophagus. Case Presentation

Management of Barrett s Esophagus. Case Presentation Management of Barrett s Esophagus Lauren B. Gerson MD, MSc Associate Clinical Professor, UCSF Director of Clinical Research Gastroenterology Fellowship Program California Pacific Medical Center San Francisco,

More information

Learning Objectives:

Learning Objectives: Crescent City GI Update 2018 Ochsner Clinic, NOLA Optimizing Endoscopic Evaluation of Barrett s Esophagus What Should I Do in My Practice? Gregory G. Ginsberg, M.D. Professor of Medicine University of

More information

Barrett s Esophagus: State of the Art. Food Getting Stuck

Barrett s Esophagus: State of the Art. Food Getting Stuck Barrett s Esophagus: State of the Art Nicholas J. Shaheen, MD, MPH Center for Esophageal Diseases and Swallowing University of North Carolina SOM Food Getting Stuck 73-year-old retired Wilmington police

More information

TECHNICAL APPENDIX. Accompanying the manuscript: Development of an Empirically Calibrated Model of Gastric Cancer in Two High-Risk Countries

TECHNICAL APPENDIX. Accompanying the manuscript: Development of an Empirically Calibrated Model of Gastric Cancer in Two High-Risk Countries TECHNICAL APPENDIX Accompanying the manuscript: Development of an Empirically Calibrated Model of Gastric Cancer in Two High-Risk Countries Jennifer M. Yeh, PhD 1 Karen M. Kuntz, ScD 2 Majid Ezzati, PhD

More information

Functional Dyspepsia. Norbert Welkovics Heine van der Walt

Functional Dyspepsia. Norbert Welkovics Heine van der Walt Norbert Welkovics Heine van der Walt Characteristics: Central abdomen Pain or discomfort Not associated with bowel movements No structural or biochemical abnormalty Definition Part of Gastroduodenal disorders

More information

The significance of Helicobacter pylori in the approach of dyspepsia in primary care Arents, Nicolaas Lodevikus Augustinus

The significance of Helicobacter pylori in the approach of dyspepsia in primary care Arents, Nicolaas Lodevikus Augustinus University of Groningen The significance of Helicobacter pylori in the approach of dyspepsia in primary care Arents, Nicolaas Lodevikus Augustinus IMPORTANT NOTE: You are advised to consult the publisher's

More information

Non-Ulcer Dyspepsia: what is it? What can we do with these patients? Overview. Dyspepsia Definition. Functional Dyspepsia. Dyspepsia the Basics

Non-Ulcer Dyspepsia: what is it? What can we do with these patients? Overview. Dyspepsia Definition. Functional Dyspepsia. Dyspepsia the Basics Non-Ulcer : what is it? What can we do with these patients? Temporal Changes and Geographic Variations in Developing Peptic Ulcer Disease Gastric Cancer 1900 Eamonn M M Quigley MD FACG Alimentary Pharmabiotic

More information

Guidelines NICE, not NICE and the Daily Mail. Dr Andy Poullis Consultant Gastroenterologist

Guidelines NICE, not NICE and the Daily Mail. Dr Andy Poullis Consultant Gastroenterologist Guidelines NICE, not NICE and the Daily Mail 2018 Dr Andy Poullis Consultant Gastroenterologist Coeliac IBS Gall bladder polyps PEI PPI Who to test for Coeliac persistent unexplained abdominal or gastrointestinal

More information

Walking, even minimal, lowers death risk!

Walking, even minimal, lowers death risk! Max Institute of Cancer Care Shalimar Bagh, Volume 1 Walking, even minimal, lowers death risk! Regular walking, even when it's below the minimum recommended levels for physical fitness, is associated with

More information

HELICOBACTER PYLORI UPDATE

HELICOBACTER PYLORI UPDATE HELICOBACTER PYLORI UPDATE PROF. TAWHEED MOWAFY DEAN OF AZAL FACULTY OF MEDICINE INTRODUCTION (H. pylori) is recognised as the most common chronic human bacterial infection,1 affecting up to 50% of the

More information

Quality ID #249 (NQF 1854): Barrett s Esophagus National Quality Strategy Domain: Effective Clinical Care

Quality ID #249 (NQF 1854): Barrett s Esophagus National Quality Strategy Domain: Effective Clinical Care Quality ID #249 (NQF 1854): Barrett s Esophagus National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Process DESCRIPTION: Percentage

More information

Efficacy of standard triple therapy versus bismuth-based quadruple therapy for eradication of Helicobacter Pylori infection

Efficacy of standard triple therapy versus bismuth-based quadruple therapy for eradication of Helicobacter Pylori infection Efficacy of standard triple therapy versus bismuth-based quadruple therapy for eradication of Helicobacter Pylori infection Ramin Talaie Modarress Hospital, Shahid Beheshti University of Medical Sciences,

More information

Gilles Jequier. Commercial Director Organobalance, a Novozymes Company

Gilles Jequier. Commercial Director Organobalance, a Novozymes Company "Latest clinical Evidences showing that a proprietary Lactobacillus reuteri Strain can reduce the Symptoms associated with a Helicobacter pylori Infection" Gilles Jequier Commercial Director Organobalance,

More information

Barrett s Esophagus: Ablate Everyone?

Barrett s Esophagus: Ablate Everyone? Nicholas J. Shaheen, MD, MPH, FACG Barrett s Esophagus: Ablate Everyone? Nicholas J. Shaheen, MD, MPH, FACG Center for Esophageal Diseases and Swallowing University of North Carolina Greetings from UNC,

More information

Frequency of Barrett Esophagus in Patients with Symptoms of Gastroesophageal Reflux Disease

Frequency of Barrett Esophagus in Patients with Symptoms of Gastroesophageal Reflux Disease Original Article Frequency of Barrett Esophagus in Patients with Symptoms of Gastroesophageal Reflux Disease From Military Hospital, Rawalpindi Obaid Ullah Khan, Abdul Rasheed Correspondence: Dr. Abdul

More information

Comparison of the Accuracy of Two Commercial Rapid Urase Tests, CLOtest and Pronto Dry, in Detecting Helicobacter pylori Infection ABSTRACT

Comparison of the Accuracy of Two Commercial Rapid Urase Tests, CLOtest and Pronto Dry, in Detecting Helicobacter pylori Infection ABSTRACT Original Article Rojborwonwitaya J, Vijitjunyakul N THAI J GASTROENTEROL 2005 Vol. 6 No. 2 May - Aug. 2005 55 Comparison of the Accuracy of Two Commercial Rapid Urase Tests, CLOtest and Pronto Dry, in

More information

Pathology of the oesophagus and the stomach. Neil A Shepherd Gloucester, UK. Bristol Pathology 1 st Year Training School, The layers of the GI tract

Pathology of the oesophagus and the stomach. Neil A Shepherd Gloucester, UK. Bristol Pathology 1 st Year Training School, The layers of the GI tract Pathology of the oesophagus and the stomach Neil A Shepherd Gloucester, UK Bristol Pathology 1 st Year Training School, The layers of the GI tract 1 Some facts about Histopathology and the upper GI tract

More information

Quality ID #249 (NQF 1854): Barrett s Esophagus National Quality Strategy Domain: Effective Clinical Care

Quality ID #249 (NQF 1854): Barrett s Esophagus National Quality Strategy Domain: Effective Clinical Care Quality ID #249 (NQF 1854): Barrett s Esophagus National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS ONLY MEASURE TYPE: Process DESCRIPTION: Percentage

More information

The Association of CagA + Helicobacter pylori Infection and Gastric Carcinoma

The Association of CagA + Helicobacter pylori Infection and Gastric Carcinoma The Association of CagA + Helicobacter pylori Infection and Gastric Carcinoma PRESENTER: Dr. Md. Khalilur Rahman Student of M.D.(Internal Medicine) Sylhet MAG Osmani Medical College Gastric Cancer- ranked

More information

Clinical Policy Title: Noninvasive testing for H. pylori

Clinical Policy Title: Noninvasive testing for H. pylori Clinical Policy Title: Noninvasive testing for H. pylori Clinical Policy Number: 08.01.05 Effective Date: January 1, 2016 Initial Review Date: August 19, 2015 Most Recent Review Date: July 3, 2018 Next

More information